On February 3, 2021, we bought additional 30 shares of Viatris (NASDAQ: VTRS) paying $17.81 per share for our Partnership Fund. Viatris is the latest addition to our Partnership fund.
VTRS is a spinoff from Pfizer stock (which we hold already 100 shares), and it was decided to keep investing in this stock until we will reach 100 shares and will be able to sell covered calls on it.
We are now holding 100 shares of VTRS in our Partnership Fund portfolio
Using dollar-cost averaging our average cost per one VTRS share is $16.48
As we have reached 100 shares, we sold a covered call: Sold 1 Covered Call on VTRS - Potential income return 17.45% in 23 days
By now VTRS takes 4.01% from our US stock portfolio.
About Viatris
Viatris is a global pharmaceutical company that believes in healthcare not as it is, but as it should be
